A new radiotherapy for advanced prostate cancer has delivered positive results in a Phase 3 trial when compared with a standard of care for the disease, Novartis announced on 23 March. Lu-PSMA-617 met both primary endpoints of the trial, improving both overall survival and radiographic progression-free survival. The trial enrolled patients whose disease had progressed following prior taxane and androgen receptor-directed therapies.
